Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jun 30;21(1):623.
doi: 10.1186/s12879-021-06347-6.

Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens

Paul A Granato  1   2 , Simon R Kimball  3 , Brenda R Alkins  3 , Deirdre C Cross  4 , Melissa M Unz  3
Affiliations
Comparative Study

Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens

Paul A Granato et al. BMC Infect Dis. .

Abstract

Purpose: With over 50 SARS-CoV-2 gene amplification assays that have been EUA cleared with minimal experimental validation performed, it is likely that not all of these assays are comparable in their ability to detect SARS-CoV-2 in clinical specimens. Thermo Fisher Scientific is a relatively new company in the molecular diagnostics field and the purpose of this study was to compare the performance of the Thermo Fisher TaqPath™ Combo Kit with an established test, the Cepheid Xpert® Xpress SARS-CoV-2 assay, for its ability to detect SARS-CoV-2 in nasopharyngeal specimens.

Methods: A total of 300 randomly selected nasopharyngeal specimens were evaluated and tested by the TaqPath and GeneXpert assays. Discordant test specimens were arbitrated by performing an alternative PCR assay and Sanger sequencing.

Results: The TaqPath assay had a 96.7 and 99.6% positive and negative agreement respectively when compared to the Xpert Xpress test. However, after test arbitration, the three discordant specimens were arbitrated in favor of the TaqPath assay producing a positive and negative percent agreement of 100% for the TaqPath Combo Kit while the Xpress SARS-CoV-2 assay had a positive and negative percent agreement of 98.3 and 99.2% respectively.

Conclusions: The TaqPath Combo Kit is a high complexity assay that compares favorably with the Xpert Xpress test and can be reliably used for the detection of SARS-CoV-2 in nasopharyngeal specimens.

Keywords: COVID-19; Gene amplification tests; PCR; SARS-CoV-2; Sanger sequencing; TaqPath combo kit; Xpert Xpress SARS-CoV-2 assay.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial or competing interests to disclose.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. CDC . Situation summary. 2020.
    1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zha L, Tan W. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi: 10.1016/50140-6736(20)30251-8. - DOI - PMC - PubMed
    1. WHO . WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. 2020.
    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SAR-CoV-2. Nat Microbial. 2020;5(4):536–544. doi: 10.1038/541564-020-0695-2. - DOI - PMC - PubMed
    1. WHO. 2020. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 March 2020. https://www.who.int/dg/speeches/deatil/who-director-general-s-opening-re....

Publication types